Overview

Procuring a molecular profiling service is a different exercise from buying a finished dosage form. A 106-gene solid tumor NGS assay is purchased as a laboratory workflow, so acceptance criteria, shipping conditions, report format and data delivery all need to be fixed in writing before the first specimen moves. Buyers who treat the purchase as an interchangeable commodity usually discover the gaps late, when a sample is rejected or a report arrives without the annotation their clinicians expected.

Specimen Acceptance and Pre-Analytical Rules

Most solid tumor panels are validated on formalin-fixed, paraffin-embedded tissue, and the acceptance thresholds are laboratory-specific rather than universal. Commonly published minimums include a tumor cell content of around 20 percent, a defined tissue area or number of unstained sections, and a minimum DNA input for library preparation; some workflows also require RNA when fusion detection is part of the panel. Because these limits vary by assay, the buyer should obtain the laboratory's written specimen manual during negotiation rather than after contracting.

Pre-analytical handling deserves equal attention. FFPE blocks and unstained slides are generally stable at ambient temperature, while extracted nucleic acid usually requires frozen storage, so a shipment that is lyophilised or already extracted carries different logistics than a paraffin block. Decalcifying fixatives, heavy-metal fixatives and improper formalin exposure are frequent causes of assay failure, which is why a clear rejection-and-repeat policy — including who bears the cost of a repeat — belongs in the commercial terms.

Commercial Terms, Timelines and Documentation

Turnaround time is the clause most often left vague. Published solid tumor NGS services range from a few working days for rapid panels to around two to three weeks for standard comprehensive workflows, so the contract should state whether the clock starts at specimen receipt or at qualification, whether preliminary results are released, and what happens when repeat testing is triggered by low input.

Documentation is the second negotiation point. Buyers typically ask for the laboratory's accreditation status (such as CAP/CLIA or ISO 15189), the validated gene list and variant classes covered, analytical sensitivity expressed as a variant allele frequency threshold, and a sample report. For cross-border work, confirm in advance how human-derived material may be exported, what consent documentation is required, and how patient data will be stored or deleted, since these obligations sit with the sender as much as with the laboratory.

FAQ

Q: What specimen types are normally accepted for a 106-gene solid tumor NGS panel? A: FFPE tissue is the default input, supplied either as a paraffin block or as unstained sections on slides, with a companion H&E slide for pathology review. Many laboratories will accept extracted DNA only when tissue is unavailable, and some require paired RNA if gene fusions are reported. Always confirm the minimum tumor content and section thickness with the performing laboratory before shipping.

Q: Which turnaround-time details should a contract specify? A: State explicitly what the clock starts from — receipt at the laboratory versus completion of specimen qualification — and include the handling of failed runs, low-input repeats and add-on requests. Ask whether rush processing is offered and whether an interim result is issued for urgent cases.

Q: What quality documents should a buyer request before signing? A: Request the accreditation certificate, the validated gene list with the variant types covered (SNVs, indels, copy-number changes, fusions), the stated analytical sensitivity, a redacted sample report, and the laboratory's specimen rejection policy. For international shipments, also request the required consent and data-handling documentation for human-derived material.